This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2010 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: October 28, 2010
Last updated: NA
Last verified: October 2010
History: No changes posted

RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving cisplatin together with radiation therapy may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of cisplatin given together with radiation therapy in treating patients with locally advanced cervical cancer.

Condition Intervention Phase
Cervical Cancer Drug: cisplatin Radiation: intensity-modulated radiation therapy Phase 1 Phase 2

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: DEPICT: A Phase I/II, Multi-Center Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Grade 3 gastrointestinal toxicity at 6 months as defined by CTCAE v 3.0

Secondary Outcome Measures:
  • Response rate assessed radiologically at 3 and 12 months
  • Local control of the disease at 2 years
  • Late toxicity at 2 years as defined by CTCAE v 3.0

Estimated Enrollment: 44
Study Start Date: July 2010
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Detailed Description:



  • To determine the feasibility of dose-escalation of chemoradiotherapy comprising cisplatin in combination with simultaneous-boost intensity-modulated radiotherapy (IMRT) in patients with locally advanced cervical cancer.


  • To assess the objective response rates in patients treated with this regimen.
  • To assess the local control of the disease in patients treated with this regimen.
  • To correlate toxicity with dose-volume histogram data in these patients.

OUTLINE: This is a multicenter, phase I, dose-escalation study followed by a phase II study.

Patients receive cisplatin IV over 1 hour weekly for up to 5 weeks. Patients also undergo intensity-modulated radiotherapy 5 days a week for approximately 6 weeks.

Patients complete a quality-of-life questionnaire at baseline, during, and after completion of study therapy.

After completion of study treatment, patients are followed up at 4 and 12 weeks, every 3 months for 2 years, and then periodically for 5 years.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed squamous cell carcinoma, adenocarcinoma, or poorly differentiated carcinoma of the cervix

    • Locally advanced disease

      • FIGO stage IIB-IVA (any pelvic nodal status) or FIGO stage IB2 and IIA (with pelvic nodal involvement)
  • Measurable disease on MRI scan
  • No evidence of common iliac or para-aortic nodal involvement
  • No distant metastases


  • WHO performance status 0-1
  • Platelet count > 100 x 10^9/L
  • White cell count > 3.0 x 10^9/L
  • Neutrophil count > 1.5 x 10^9/L
  • ALT/AST < 2.5 times upper limit of normal (ULN)
  • Bilirubin < 1.25 times ULN
  • EDTA clearance > 55 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No prior cancer except skin tumor
  • No prior pelvic adhesions, inflammatory bowel disease, pelvic inflammatory disease, or diabetes mellitus


  • No prior pelvic radiotherapy or surgery other than laparoscopic node dissection
  • No other concurrent anticancer or investigational therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01230996

United Kingdom
Saint Bartholomew's Hospital Recruiting
London, England, United Kingdom, EC1A 7BE
Contact: Contact Person    44-20-7882-8490   
Royal Marsden - London Recruiting
London, England, United Kingdom, SW3 6JJ
Contact: Contact Person    44-20-7808-2581      
Hammersmith Hospital Recruiting
London, England, United Kingdom, W12 0HF
Contact: Contact Person    44-20-8383-1000      
Sponsors and Collaborators
St. Bartholomew's Hospital
Principal Investigator: Melanie Powell St. Bartholomew's Hospital
  More Information Identifier: NCT01230996     History of Changes
Other Study ID Numbers: CDR0000687340
Study First Received: October 28, 2010
Last Updated: October 28, 2010

Keywords provided by National Cancer Institute (NCI):
cervical adenocarcinoma
cervical adenosquamous cell carcinoma
cervical squamous cell carcinoma
stage IB cervical cancer
stage IIA cervical cancer
stage IIB cervical cancer
stage III cervical cancer
stage IVA cervical cancer

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Antineoplastic Agents processed this record on August 18, 2017